Read as much as you want on BostonGlobe.com, anywhere and anytime, for just 99¢.

Bruins Live

2

1

2nd Intermission

Mass. Movers

FDA report lifts Aegerion drug

istockphoto.com

Continue reading below

Aegerion Pharmaceuticals Inc. shares jumped Monday after Food and Drug Administration medical reviewers said the Cambridge firm’s proposed drug to treat a rare genetic disorder that causes high cholesterol is effective at reducing it, but there is a potential to cause liver damage. The drug, lomitapide, will be reviewed on Wednesday by a panel of non-FDA medical specialists, which will make recommendations to the agency about whether lomitapide should be approved.

Loading comments...
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com